Evidence map›Paper›PMID 42189047›Full record

ArticleDrug delivery2026

Self-assembled non-steroidal anti-inflammatory drug-peptide hydrogel to effectively mitigate ocular inflammation.

Yuhan Hu, Yu Li, Yuqin Wu, Yutuo Zhu, Jinrun Chen, Yinghao Ding, Zhimou Yang, Xingyi Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuhan HuKey Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Collaborative Innovation Center of Chemical Science and Engineering, and National Institute of Functional Materials, Nankai University, Tianjin, China.
Yu LiNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Yuqin WuNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Yutuo ZhuNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Jinrun ChenNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Yinghao DingKey Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Collaborative Innovation Center of Chemical Science and Engineering, and National Institute of Functional Materials, Nankai University, Tianjin, China.
Zhimou YangKey Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Collaborative Innovation Center of Chemical Science and Engineering, and National Institute of Functional Materials, Nankai University, Tianjin, China.
Xingyi LiNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pranoprofen (Pra) eye drop has been widely used in clinical practice for the efficient mitigation of ocular inflammation, but it often suffers from poor bioavailability owing to the existence of various ocular barriers (i.e. tear barrier and corneal epithelial barrier). In this study, we rationally designed and synthesized a Pra-peptide conjugate using a D-form tripeptide (i.e. phenylalanine-phenylalanine-aspartic acid; ffd) motif, and the resulting conjugate (i.e. Pra-ffd) spontaneously self-assembled into single-component supramolecular hydrogel for efficient mitigation of ocular inflammation. The generated hydrogel was thoroughly characterized using a rheometer and transmission electron microscopy (TEM). The proposed Pra-ffd hardly caused cytotoxicity in RAW 264.7, L929, and human corneal epithelial cells (HCEC). The Pra-ffd hydrogel dose-dependently reduced the levels of proinflammatory cytokines (e.g. PGE

Indexed as

Anti-Inflammatory Agents, Non-SteroidalHydrogelsInflammationPeptidesUveitisAnimalsBiological AvailabilityCytokinesHumansMiceOligopeptidesOphthalmic SolutionsRabbitsRAW 264.7 CellsReactive Oxygen SpeciesAnti-Inflammatory Agents, Non-SteroidalCytokinesHydrogelsOligopeptidesOphthalmic SolutionsPeptidesReactive Oxygen Speciesdrug-peptide conjugateocular drug deliverysupramolecular hydrogeltopical instillationUveitis

Identifiers

PMID42189047
PMCPMC13215406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.